Search Videos by Topic or Participant
Browse by Series:

Deciding Treatment Options for Early-Stage Prostate Cancer

Panelists: Mark S. Austenfeld, MD, Kansas City Urology Care; Raoul S. Concepcion, MD, Urology Associates, PC; E. David Crawford, MD, University of Colorado;
Published: Tuesday, Sep 04, 2012


As the primary purveyors of prostate cancer treatment, urologists need to ensure their practices are set up to guide patients from diagnosis to treatment. The challenge of identifying the appropriate patients for early treatment remains an issue that needs addressed in many practices.

Neal D. Shore, MD, is excited about the possible addition of new biomarkers to the traditional set of parameters, such as biopsy and digital rectal exam. Shore believes that the utilization biopsy samples for cell cycle gene sequences will aid in patient selection, active surveillance eligibility, and determining the aggressiveness of therapy.

Once the correct patient is selected, the challenge becomes choosing from the plethora of options for localized therapy. Moderator, Raoul S. Concepcion, MD, and Shore agree that a large integrated group model is likely the best approach for selecting the most appropriate therapy. The establishment of tumor boards and centers of excellence is essential to provide the best care for the patient in the most efficient and cost-effective way.
Slider Left
Slider Right


As the primary purveyors of prostate cancer treatment, urologists need to ensure their practices are set up to guide patients from diagnosis to treatment. The challenge of identifying the appropriate patients for early treatment remains an issue that needs addressed in many practices.

Neal D. Shore, MD, is excited about the possible addition of new biomarkers to the traditional set of parameters, such as biopsy and digital rectal exam. Shore believes that the utilization biopsy samples for cell cycle gene sequences will aid in patient selection, active surveillance eligibility, and determining the aggressiveness of therapy.

Once the correct patient is selected, the challenge becomes choosing from the plethora of options for localized therapy. Moderator, Raoul S. Concepcion, MD, and Shore agree that a large integrated group model is likely the best approach for selecting the most appropriate therapy. The establishment of tumor boards and centers of excellence is essential to provide the best care for the patient in the most efficient and cost-effective way.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x